Novo Nordisk Ends Lawsuit, Offers Ozempic and Wegovy via Hims at $149–$299
Novo Nordisk will distribute its Ozempic and Wegovy injectables and Wegovy pill through Hims & Hers at its self-pay prices of $149–$299 per month, ending its lawsuit over Hims’ compounded GLP-1 copycats. The deal follows over 600,000 Wegovy pill prescriptions since launch and boosts telehealth access to its obesity treatments.
1. Partnership Overview
Novo Nordisk has agreed to supply its branded Ozempic and Wegovy injectables, as well as the newly launched Wegovy pill, through the Hims & Hers telehealth platform. Under the partnership, Hims will distribute these FDA-approved products at Novo’s standard self-pay prices ranging from $149 to $299 per month.
2. Legal Dispute Resolution
The agreement resolves a legal dispute initiated in February over Hims’ sale of compounded GLP-1 alternatives, leading Novo to drop its lawsuit and Hims to cease advertising unapproved versions. The move also follows planned FDA legal action against mass-marketed copycat drugs.
3. Pricing and Prescription Data
Since its launch two months ago, the Wegovy pill has amassed over 600,000 prescriptions, demonstrating strong patient uptake. Novo’s price reduction from around $1,000 to $149–$299 per month has been designed to enhance affordability and drive broader telehealth adoption.
4. Competitive Landscape
The deal strengthens Novo Nordisk’s position against market leader Eli Lilly by expanding distribution channels and leveraging telehealth growth. It also underscores the strategic importance of partnerships to maintain market share in the competitive GLP-1 obesity treatment segment.